Cargando…
Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are learning the variable patterns associated with extende...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495986/ https://www.ncbi.nlm.nih.gov/pubmed/37706179 http://dx.doi.org/10.3389/fonc.2023.1217179 |
_version_ | 1785105011668156416 |
---|---|
author | Dar, Nakul Gradecki, Sarah E. Gaughan, Elizabeth M. |
author_facet | Dar, Nakul Gradecki, Sarah E. Gaughan, Elizabeth M. |
author_sort | Dar, Nakul |
collection | PubMed |
description | Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are learning the variable patterns associated with extended clinical courses. Sarcoidosis is characterized by non-caseating granulomatous inflammation of unknown etiology, often presenting with cutaneous, lung, or lymph node involvement. There is a known association between sarcoidosis and melanoma, and sarcoidosis is increasingly seen and described in the setting of anti-melanoma therapy. The challenge for clinicians is to differentiate between sarcoid-related and malignancy-related findings, which may follow a variable course over years. We present two cases of BRAF and MEK inhibitor-related sarcoidosis in patients with melanoma and review the literature. The dynamic nature of the clinical and radiographic findings impacted patient management and clinical decisions for years of their treatment course. |
format | Online Article Text |
id | pubmed-10495986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104959862023-09-13 Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma Dar, Nakul Gradecki, Sarah E. Gaughan, Elizabeth M. Front Oncol Oncology Targeted therapies, including BRAF and MEK inhibitors, are valuable treatment options for patients with unresectable or metastatic BRAF V600-mutant melanoma. With the improvement in survival seen with modern melanoma therapeutics, clinicians are learning the variable patterns associated with extended clinical courses. Sarcoidosis is characterized by non-caseating granulomatous inflammation of unknown etiology, often presenting with cutaneous, lung, or lymph node involvement. There is a known association between sarcoidosis and melanoma, and sarcoidosis is increasingly seen and described in the setting of anti-melanoma therapy. The challenge for clinicians is to differentiate between sarcoid-related and malignancy-related findings, which may follow a variable course over years. We present two cases of BRAF and MEK inhibitor-related sarcoidosis in patients with melanoma and review the literature. The dynamic nature of the clinical and radiographic findings impacted patient management and clinical decisions for years of their treatment course. Frontiers Media S.A. 2023-08-29 /pmc/articles/PMC10495986/ /pubmed/37706179 http://dx.doi.org/10.3389/fonc.2023.1217179 Text en Copyright © 2023 Dar, Gradecki and Gaughan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Dar, Nakul Gradecki, Sarah E. Gaughan, Elizabeth M. Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma |
title | Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma |
title_full | Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma |
title_fullStr | Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma |
title_full_unstemmed | Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma |
title_short | Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma |
title_sort | case report: dynamic overlap of melanoma, sarcoidosis, and targeted therapy for braf-mutant melanoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495986/ https://www.ncbi.nlm.nih.gov/pubmed/37706179 http://dx.doi.org/10.3389/fonc.2023.1217179 |
work_keys_str_mv | AT darnakul casereportdynamicoverlapofmelanomasarcoidosisandtargetedtherapyforbrafmutantmelanoma AT gradeckisarahe casereportdynamicoverlapofmelanomasarcoidosisandtargetedtherapyforbrafmutantmelanoma AT gaughanelizabethm casereportdynamicoverlapofmelanomasarcoidosisandtargetedtherapyforbrafmutantmelanoma |